Enhancing Motor Learning with a Single Dose of Modafinil or Fluoxetine

Enhancing Motor Learning with a Single Dose of Modafinil or Fluoxetine - Improving motor learning

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42762

Enrollment

166

Registered

2015-07-03

Start date

2016-02-24

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

n.a.

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy Male Aged 18-55 years Informed consent obtained

Exclusion criteria

Exclusion criteria: History of neurological or psychiatric disorders History of neurosurgery History of Sleep disorders History or evidence of renal, gastrointestinal, hepatic or hematologic abnormalities Using acute or chronic psychoactive drugs Alcoholism Smoking

Design outcomes

Primary

Measure	Time frame
The main objective of the study is to determine the effect of modafinil and fluoxetine on motor learning in healthy individuals. The participants will be subjected to two different cerebellar specific motor adaptation paradigms: the random saccade adaption task (motor timing independent) and the random smooth pursuit adaptation task (motor timing dependent). The motor learning capacity will be determined by quantifying the velocity and gain of adaptation. A minimal drug-induced improvement of the motor learning capacity by 10% is considered clinically relevant.	—

Measure

Time frame

The main objective of the study is to determine the effect of modafinil and fluoxetine on motor learning in healthy individuals. The participants will be subjected to two different cerebellar specific motor adaptation paradigms: the random saccade adaption task (motor timing independent) and the random smooth pursuit adaptation task (motor timing dependent). The motor learning capacity will be determined by quantifying the velocity and gain of adaptation. A minimal drug-induced improvement of the motor learning capacity by 10% is considered clinically relevant.

—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results